8,024 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Acquired by BDF Gestion

BDF Gestion bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,024 shares of the medical equipment provider’s stock, valued at approximately $3,569,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Creekmur Asset Management LLC raised its holdings in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 42 shares in the last quarter. Delos Wealth Advisors LLC raised its holdings in Intuitive Surgical by 380.0% during the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. LRI Investments LLC bought a new stake in Intuitive Surgical during the first quarter worth approximately $30,000. Baystate Wealth Management LLC raised its holdings in Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 45 shares in the last quarter. Finally, MCF Advisors LLC grew its position in Intuitive Surgical by 108.1% in the fourth quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 40 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ISRG. Truist Financial lifted their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $380.00 to $510.00 in a research report on Friday, August 2nd. Morgan Stanley lifted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Barclays lifted their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group began coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus price target of $442.30.

Intuitive Surgical Stock Down 0.0 %

Shares of NASDAQ:ISRG traded down $0.19 during trading on Friday, reaching $463.43. 1,015,313 shares of the company traded hands, compared to its average volume of 1,568,958. The firm has a fifty day simple moving average of $435.94 and a 200 day simple moving average of $403.41. The firm has a market cap of $164.38 billion, a P/E ratio of 83.23, a price-to-earnings-growth ratio of 4.97 and a beta of 1.39. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $468.78.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. As a group, research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Robert Desantis sold 284 shares of Intuitive Surgical stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $110,521.44. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,142,714.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Robert Desantis sold 284 shares of Intuitive Surgical stock in a transaction on Monday, May 13th. The shares were sold at an average price of $389.16, for a total value of $110,521.44. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,142,714.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Myriam Curet sold 2,818 shares of Intuitive Surgical stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $136,522.74. The disclosure for this sale can be found here. Insiders sold 15,766 shares of company stock valued at $6,802,276 in the last quarter. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.